News 
Market Data 
Discover
dstock07734
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gary,
When was the contract on RWE between NICE and flatiron started? Was it before the commercial manufacturing license at Sawston approved?
I assume you do agree that at least two to five hundred patients received the DCVax-L related treatment before the submission of the application package.
Keep in mind NWBO said the package was filed. No place it was said specifically what type of approval they were filing. Would UK want to be the first one to approval a cell therapy based on RWE if such a chance was given? Absolutely!
https://resources.flatiron.com/press/press-release/nice-partnership-2020
beartrap,
How is it possible that they would file the approval for DCVax-L alone combined with SOC? Have we heard Les mentioned that last year in three months 200 patients received the treatments? Have we heard from any gofunding case in which the patient talked about receiving chemo while receiving DCVax-L since 2016?
Did you see three cases on t-cell expansion? See the numbers were measured at 4th month and 8th month. These three patients are from the p3 trial which means those numbers were obtained at least before 2015. Would the company measure all these numbers for patients in the compassionate use program? Absolutely. 
I know every one wants to be conservative on their estimate. Let's try to be conservative by using the combo trial as an illustration.
Would you agree the outcome measures adopted in the combo trial are radical, disruptive, and revolutionary? They gotta be since we cannot find such measures in any other trials on immunotherapy. I once wrote a post claiming that the combo trial was implied in then NCI director Monica Bertagnolli's report. The trial also has Merck as one of the collaborators. For a trial of such magnitude, none of participants can afford to adopt the measures that the trial results in the end could not meet. They have to conservative. Should we ask ourselves the question: what could give the trial designers the confidence so that they were bold enough to adopt such measures? The answer is simple. They have been using measures like these somewhere else. They can only have the data on these type measures from the compassionate use program. That's the only source. Now they would like to see if such measures would produce better results by including keytruda. Is DCVax-L in combination with poly-iclc the placebo?
Every investor likes something deterministic. But I suspect retailers can earn money once something becomes deterministic. I hope in the end if I am right, someone on this board could buy me a beer. LoL.
IC,
Do you recall I was the first one on this board who correlated the following figure with the p3 trial? I believe I was also the first one who said something exciting was going to happen between one and two months based on the information in the post by the President of Oncovir. One month after his post, the article on prostate cancer showed up. Exactly two months after his post, the Nature article showed up. I have been repeatedly mentioning about the secrete colorectal trial which will be published definitely before the PDUFA of Roche's SC Tecentriq.
If you give me credit on the above, you should listen to me one more time: you are not on the winning side.
Did you get someone else's medical record without consent? Or did you photoshop the medical records? Either way the two neurosurgeons are listed in the records. Did you impersonate as a former government employees and a former solider? You said you submitted your narratives to NICE and MHRA. What if Laura cannot find the narratives? The company can sue you for libel. Ask your boss to answer those questions.
Thank you for sharing your critical thinking.
I don't know the answer to my questions. As a matter of fact, I have more questions.
Was the analysis as mentioned in the unpublished paper carried out before the re-ignition of the Moonshot program?
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249282
https://www.whitehouse.gov/briefing-room/statements-releases/2022/02/02/fact-sheet-president-biden-reignites-cancer-moonshot-to-end-cancer-as-we-know-it/
I have no affirmative answer. Based on the words in 10Q from August 2020, it could be
As the Company recently reported, this process has been completed and all of the trial sites are now finished. The data from the trial sites comprises most, though not all, of the data required for analyzing the trial. The remaining required data includes information from specialized vendors -- for example, genetic profiles such as IDH mutations. When this external data joins the now locked data from the trial sites, the overall trial dataset will be locked.
In 2021, NCI launched the Glioblastoma Therapeutics Network (GTN), a national multi-institutional collaborative effort with the goal of taking novel therapeutic agents from preclinical studies in models of GBM into pilot clinical studies that include biomarkers of effects.
IC,
How do you feel this part from 10Q? I do think you need to give me credit for being the one who has been preaching the idea of NWBO collaboration with BPs.
The Company also continued discussions and negotiations during the first quarter of 2024 relating to collaborations which the Company believes will help it build a broad franchise in dendritic cell-based immunotherapies.
Size exclusion chromatography (SEC) is the analytical “gold standard” for the separation and accurate quantitation of aggregates, monomers, and lower molecular weight fragments contained in biotherapeutic peptides and proteins, including monoclonal antibody (mAbs) drugs.
— d_stock (@d_stock07734) March 30, 2024
Did…
Amgen
— d_stock (@d_stock07734) March 29, 2024
Postdoctoral Fellow – Immunology (autoimmunity and inflammation) https://t.co/8hlyzsT2id
Expertise with mouse handling, in vivo rodent models, multi-color flow cytometry, isolation and culture of primary human and mouse cells and cell lines, cell engineering, scRNA-seq,…
A wish and a dream? Is that what you are thinking?
See the following figure? The pink dots are the t cells loaded with tumor-associated antigen infiltrating tumor sites to kill cancer cells. The normal human has 2 to 20 t cells. At one point, I was trying to manually count the number of t cells in the figure to have a precise idea on the t-cell expansion magnitude. I failed. But thanks to ChatGPT, I finally got the number. It is 911 if I remember correctly. Do you think someone so serious about everything related to NWBO would believe in a wish or a dream?
You probably hold grudge against me simply because I nailed your boss. I could be wrong. Maybe nemesis18 is not your boss. But he has a bunch of minions on this board.
